Baseline characteristics
| . | All clonotyped patients . | Cohort 1 . | Cohort 2 . | Cohort 3 . |
|---|---|---|---|---|
| N | 116 | 56 (48%) | 37 (32%) | 23 (20%) |
| Male | 69 (59%) | 31 (55%) | 23 (62%) | 15 (65%) |
| Median age at ASCT (range) | 59 (23-77) | 60 (39-77) | 59 (30-77) | 57 (23-76) |
| Diagnosis | ||||
| DLBCL NOS | 75 (65%) | 34 (61%) | 26 (70%) | 15 (65%) |
| TIL | 34 (29%) | 20 (36%) | 10 (27%) | 4 (17%) |
| PMBCL | 7 (6%) | 2 (4%) | 1 (3%) | 4 (17%) |
| DEL | ||||
| Yes | 3 (28%) | 28 (50%) | 3 (8%) | 2 (9%) |
| No | 61 (53%) | 27 (48%) | 16 (43%) | 18 (78%) |
| Not available | 22 (19%) | 1 (2%) | 18 (49%) | 3 (13%) |
| DHL | ||||
| Yes | 11 (9%) | 8 (15%) | 2 (5%) | 1 (4%) |
| No | 89 (77%) | 47 (85%) | 32 (86%) | 10 (43%) |
| Not available | 16 (14%) | 1 (2%) | 3 (8%) | 12 (52%) |
| Primary refractory | 36 (31%) | 20 (36%) | 9 (24%) | 7 (30%) |
| Lines of systemic therapy before ASCT | ||||
| 2 | 95 (82%) | 47 (84%) | 32 (86%) | 16 (70%) |
| 3 | 19 (16%) | 7 (12%) | 5 (14%) | 7 (30%) |
| 4 | 2 (2%) | 2 (4%) | 0 (0%) | 0 (0%) |
| Disease status at ASCT∗ | ||||
| CR | 75 (65%) | 33 (59%) | 28 (76%) | 14 (61%) |
| PR | 38 (33%) | 20 (36%) | 9 (24%) | 9 (39%) |
| SD | 3 (3%) | 3 (5%) | 0 (0%) | 0 (0%) |
| Conditioning chemotherapy | ||||
| BEAM | 59 (51%) | 0 (0%) | 37 (100%) | 22 (96%) |
| CBV | 54 (47%) | 54 (96%) | 0 (0%) | 0 (0%) |
| Other | 3 (3%) | 2 (4%) | 0 (0%) | 1 (4%) |
| ASC sample available | 98 (84%) | 56 (100%) | 36 (97%) | 6 (26%) |
| . | All clonotyped patients . | Cohort 1 . | Cohort 2 . | Cohort 3 . |
|---|---|---|---|---|
| N | 116 | 56 (48%) | 37 (32%) | 23 (20%) |
| Male | 69 (59%) | 31 (55%) | 23 (62%) | 15 (65%) |
| Median age at ASCT (range) | 59 (23-77) | 60 (39-77) | 59 (30-77) | 57 (23-76) |
| Diagnosis | ||||
| DLBCL NOS | 75 (65%) | 34 (61%) | 26 (70%) | 15 (65%) |
| TIL | 34 (29%) | 20 (36%) | 10 (27%) | 4 (17%) |
| PMBCL | 7 (6%) | 2 (4%) | 1 (3%) | 4 (17%) |
| DEL | ||||
| Yes | 3 (28%) | 28 (50%) | 3 (8%) | 2 (9%) |
| No | 61 (53%) | 27 (48%) | 16 (43%) | 18 (78%) |
| Not available | 22 (19%) | 1 (2%) | 18 (49%) | 3 (13%) |
| DHL | ||||
| Yes | 11 (9%) | 8 (15%) | 2 (5%) | 1 (4%) |
| No | 89 (77%) | 47 (85%) | 32 (86%) | 10 (43%) |
| Not available | 16 (14%) | 1 (2%) | 3 (8%) | 12 (52%) |
| Primary refractory | 36 (31%) | 20 (36%) | 9 (24%) | 7 (30%) |
| Lines of systemic therapy before ASCT | ||||
| 2 | 95 (82%) | 47 (84%) | 32 (86%) | 16 (70%) |
| 3 | 19 (16%) | 7 (12%) | 5 (14%) | 7 (30%) |
| 4 | 2 (2%) | 2 (4%) | 0 (0%) | 0 (0%) |
| Disease status at ASCT∗ | ||||
| CR | 75 (65%) | 33 (59%) | 28 (76%) | 14 (61%) |
| PR | 38 (33%) | 20 (36%) | 9 (24%) | 9 (39%) |
| SD | 3 (3%) | 3 (5%) | 0 (0%) | 0 (0%) |
| Conditioning chemotherapy | ||||
| BEAM | 59 (51%) | 0 (0%) | 37 (100%) | 22 (96%) |
| CBV | 54 (47%) | 54 (96%) | 0 (0%) | 0 (0%) |
| Other | 3 (3%) | 2 (4%) | 0 (0%) | 1 (4%) |
| ASC sample available | 98 (84%) | 56 (100%) | 36 (97%) | 6 (26%) |
BEAM, BCNU, etoposide, cytrabine, melphalan; PR, partial response; SD, stable disease.
115/116 (99%) had a PET scan for response assessment before ACST.